NURECA
|
NURECA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -8.25 | 44.96 | 46.37 | 6,395.00 | 6,226.00 |
| CEPS(Rs) | -5.86 | 46.44 | 46.80 | 967.00 | 897.57 |
| DPS(Rs) | - | 3.00 | 2.00 | - | - |
| Book NAV/Share(Rs) | 194.88 | 203.20 | 163.10 | 13,935.00 | 6,955.00 |
| Tax Rate(%) | 23.20 | 26.27 | 25.60 | 25.71 | 29.58 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -12.87 | 20.55 | 27.36 | 9.75 | 14.20 |
| EBIT Margin(%) | -8.83 | 22.85 | 28.42 | 9.44 | 14.25 |
| Pre Tax Margin(%) | -9.21 | 22.57 | 27.71 | 8.66 | 13.87 |
| PAT Margin (%) | -7.08 | 16.64 | 20.62 | 6.43 | 9.77 |
| Cash Profit Margin (%) | -5.03 | 17.19 | 20.80 | 6.81 | 9.86 |
| Performance Ratios | |||||
| ROA(%) | -3.62 | 20.33 | 41.38 | 22.30 | 40.78 |
| ROE(%) | -4.14 | 24.55 | 52.39 | 61.23 | 162.03 |
| ROCE(%) | -5.17 | 33.57 | 67.61 | 56.70 | 179.97 |
| Asset Turnover(x) | 0.51 | 1.22 | 2.01 | 3.47 | 4.18 |
| Sales/Fixed Asset(x) | 9.85 | 34.28 | 89.50 | 113.76 | 201.42 |
| Working Capital/Sales(x) | 0.66 | 1.39 | 1.39 | 4.28 | 8.30 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.10 | 0.03 | 0.01 | 0.01 | - |
| Receivable days | 11.25 | 2.11 | 10.64 | 39.93 | 30.18 |
| Inventory Days | 152.88 | 67.53 | 43.16 | 55.02 | 48.92 |
| Payable days | 23.46 | 18.53 | 26.74 | 44.04 | 68.29 |
| Valuation Parameters | |||||
| PER(x) | - | 30.30 | 12.98 | - | - |
| PCE(x) | -51.24 | 29.33 | 12.87 | - | - |
| Price/Book(x) | 1.54 | 6.70 | 3.69 | - | - |
| Yield(%) | - | 0.22 | 0.33 | - | - |
| EV/Net Sales(x) | 2.06 | 5.00 | 2.23 | 0.10 | 0.01 |
| EV/Core EBITDA(x) | -29.03 | 20.22 | 7.41 | 1.00 | 0.04 |
| EV/EBIT(x) | -22.30 | 20.71 | 7.46 | 1.04 | 0.04 |
| EV/CE(x) | 1.13 | 5.07 | 2.51 | 0.29 | 0.01 |
| M Cap / Sales | 2.70 | 5.33 | 2.82 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -56.44 | 19.72 | 114.69 | 60.63 | 208.70 |
| Core EBITDA Growth(%) | -112.51 | -1.79 | 559.74 | 6.72 | 108.08 |
| EBIT Growth(%) | -116.67 | -3.46 | 581.55 | 3.27 | 107.07 |
| PAT Growth(%) | -118.35 | -3.05 | 625.16 | 2.71 | 100.06 |
| EPS Growth(%) | -118.35 | -3.05 | -99.27 | 2.71 | 100.06 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.01 | 0.70 | 0.06 |
| Current Ratio(x) | 20.89 | 5.28 | 7.78 | 3.45 | 1.50 |
| Quick Ratio(x) | 17.03 | 3.89 | 6.24 | 1.72 | 0.62 |
| Interest Cover(x) | -22.87 | 83.30 | 39.89 | 12.14 | 37.38 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of NURECA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NURECA | ₹282.3 Cr | -5.6% | -18.7% | -6.7% | Stock Analytics | |
| POLY MEDICURE | ₹15,044.0 Cr | 5.1% | -3.2% | 67.7% | Stock Analytics | |
| PREVEST DENPRO | ₹451.2 Cr | -0.7% | -13.2% | 24.9% | Stock Analytics | |
NURECA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NURECA | -5.6% |
-18.7% |
-6.7% |
| SENSEX | -2.4% |
-1% |
21.3% |
You may also like the below Video Courses
